Cargando…

The Impacts of National Centralized Drug Procurement Policy on Drug Utilization and Drug Expenditures: The Case of Shenzhen, China

In 2019, the Chinese government implemented the first round of the National Centralized Drug Procurement (NCDP) pilot (so-called “4 + 7” policy) in mainland China, in which 25 drugs were included. We conducted this study to examine the impacts of NCDP policy on drug utilization and expenditures, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Lei, Yang, Ying, Luo, Mi, Hu, Borui, Yin, Shicheng, Mao, Zongfu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7765443/
https://www.ncbi.nlm.nih.gov/pubmed/33334027
http://dx.doi.org/10.3390/ijerph17249415
_version_ 1783628491567136768
author Chen, Lei
Yang, Ying
Luo, Mi
Hu, Borui
Yin, Shicheng
Mao, Zongfu
author_facet Chen, Lei
Yang, Ying
Luo, Mi
Hu, Borui
Yin, Shicheng
Mao, Zongfu
author_sort Chen, Lei
collection PubMed
description In 2019, the Chinese government implemented the first round of the National Centralized Drug Procurement (NCDP) pilot (so-called “4 + 7” policy) in mainland China, in which 25 drugs were included. We conducted this study to examine the impacts of NCDP policy on drug utilization and expenditures, and to clarify the main factors contributing to drug expenditure changes. This study used drug purchasing order data from the Centralized Drug Procurement Survey in Shenzhen 2019. Drugs related to the “4 + 7” policy were selected as study samples, including 23 “4 + 7” policy-related varieties and 15 basic alternative drugs. Driving factors for drug expenditures changes were analyzed using A.M. index system analysis (Addis A. & Magrini N.’ method). After the implementation of the NCDP policy, the volume of “4 + 7” policy-related varieties increased by 73.8%, among which winning products jumped by 1638.2% and non-winning products dropped by 70.8%; the expenditures of “4 + 7” policy-related varieties decreased by 36.9%. Structure effects (0.47) and price effects (0.78) negatively contributed to the increase in drug expenditures of “4 + 7” policy-related varieties, while volume effects (1.73) had positive influence. NCDP policy successfully decreased drug expenditures of “4 + 7” policy-related varieties with structure effects playing a leading role. However, total drug expenditures were not effectively controlled due to the increasing use of alternative drugs.
format Online
Article
Text
id pubmed-7765443
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-77654432020-12-27 The Impacts of National Centralized Drug Procurement Policy on Drug Utilization and Drug Expenditures: The Case of Shenzhen, China Chen, Lei Yang, Ying Luo, Mi Hu, Borui Yin, Shicheng Mao, Zongfu Int J Environ Res Public Health Article In 2019, the Chinese government implemented the first round of the National Centralized Drug Procurement (NCDP) pilot (so-called “4 + 7” policy) in mainland China, in which 25 drugs were included. We conducted this study to examine the impacts of NCDP policy on drug utilization and expenditures, and to clarify the main factors contributing to drug expenditure changes. This study used drug purchasing order data from the Centralized Drug Procurement Survey in Shenzhen 2019. Drugs related to the “4 + 7” policy were selected as study samples, including 23 “4 + 7” policy-related varieties and 15 basic alternative drugs. Driving factors for drug expenditures changes were analyzed using A.M. index system analysis (Addis A. & Magrini N.’ method). After the implementation of the NCDP policy, the volume of “4 + 7” policy-related varieties increased by 73.8%, among which winning products jumped by 1638.2% and non-winning products dropped by 70.8%; the expenditures of “4 + 7” policy-related varieties decreased by 36.9%. Structure effects (0.47) and price effects (0.78) negatively contributed to the increase in drug expenditures of “4 + 7” policy-related varieties, while volume effects (1.73) had positive influence. NCDP policy successfully decreased drug expenditures of “4 + 7” policy-related varieties with structure effects playing a leading role. However, total drug expenditures were not effectively controlled due to the increasing use of alternative drugs. MDPI 2020-12-15 2020-12 /pmc/articles/PMC7765443/ /pubmed/33334027 http://dx.doi.org/10.3390/ijerph17249415 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Chen, Lei
Yang, Ying
Luo, Mi
Hu, Borui
Yin, Shicheng
Mao, Zongfu
The Impacts of National Centralized Drug Procurement Policy on Drug Utilization and Drug Expenditures: The Case of Shenzhen, China
title The Impacts of National Centralized Drug Procurement Policy on Drug Utilization and Drug Expenditures: The Case of Shenzhen, China
title_full The Impacts of National Centralized Drug Procurement Policy on Drug Utilization and Drug Expenditures: The Case of Shenzhen, China
title_fullStr The Impacts of National Centralized Drug Procurement Policy on Drug Utilization and Drug Expenditures: The Case of Shenzhen, China
title_full_unstemmed The Impacts of National Centralized Drug Procurement Policy on Drug Utilization and Drug Expenditures: The Case of Shenzhen, China
title_short The Impacts of National Centralized Drug Procurement Policy on Drug Utilization and Drug Expenditures: The Case of Shenzhen, China
title_sort impacts of national centralized drug procurement policy on drug utilization and drug expenditures: the case of shenzhen, china
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7765443/
https://www.ncbi.nlm.nih.gov/pubmed/33334027
http://dx.doi.org/10.3390/ijerph17249415
work_keys_str_mv AT chenlei theimpactsofnationalcentralizeddrugprocurementpolicyondrugutilizationanddrugexpendituresthecaseofshenzhenchina
AT yangying theimpactsofnationalcentralizeddrugprocurementpolicyondrugutilizationanddrugexpendituresthecaseofshenzhenchina
AT luomi theimpactsofnationalcentralizeddrugprocurementpolicyondrugutilizationanddrugexpendituresthecaseofshenzhenchina
AT huborui theimpactsofnationalcentralizeddrugprocurementpolicyondrugutilizationanddrugexpendituresthecaseofshenzhenchina
AT yinshicheng theimpactsofnationalcentralizeddrugprocurementpolicyondrugutilizationanddrugexpendituresthecaseofshenzhenchina
AT maozongfu theimpactsofnationalcentralizeddrugprocurementpolicyondrugutilizationanddrugexpendituresthecaseofshenzhenchina
AT chenlei impactsofnationalcentralizeddrugprocurementpolicyondrugutilizationanddrugexpendituresthecaseofshenzhenchina
AT yangying impactsofnationalcentralizeddrugprocurementpolicyondrugutilizationanddrugexpendituresthecaseofshenzhenchina
AT luomi impactsofnationalcentralizeddrugprocurementpolicyondrugutilizationanddrugexpendituresthecaseofshenzhenchina
AT huborui impactsofnationalcentralizeddrugprocurementpolicyondrugutilizationanddrugexpendituresthecaseofshenzhenchina
AT yinshicheng impactsofnationalcentralizeddrugprocurementpolicyondrugutilizationanddrugexpendituresthecaseofshenzhenchina
AT maozongfu impactsofnationalcentralizeddrugprocurementpolicyondrugutilizationanddrugexpendituresthecaseofshenzhenchina